Isofol reports disease control in all evaluated patients in arfolitixorin trial

• Isofol Medical reported preliminary results on November 10, 2026, from its phase Ib/II arfolitixorin trial in metastatic colorectal cancer.
• All evaluated patients achieved disease control, with tumor shrinkage in a clear majority; one patient subsequently experienced disease progression.
• Five of 10 treated patients became candidates for potentially curative tumor surgery, unexpectedly discontinuing study treatment.
• No dose-limiting side effects have been observed, though results remain based on a limited patient population.
• The phase II expansion will cover 15-20 sites across four European countries, with parallel recruitment in Japan through partner Solasia Pharma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Isofol Medical AB published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.